STRIDES PHARMA SCIENCE LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 876.8 INR | +0.01% |
|
+3.93% | +35.04% |
| 04-09 | Strides Pharma Science Gets US FDA Nod for Fluoxetine Tabs | MT |
| 01-30 | Transcript : Strides Pharma Science Limited, Q3 2024 Earnings Call, Jan 30, 2024 |
Evolution of the average Target Price on Strides Pharma Science Limited
Price target over the last 5 years
History of analyst recommendation changes
313a7902c04bd75804fb930f8.-CxY-km2QRjxIGnJpwAfbtXiQiYdWaj792jRX3h-30M.tWIVswXbKlu2cT-jzWFZGp2UckBpL96zgDG0HBIWvDfObS6zK9krS75VKA~ec9bbab32d2ff139b4ea2675917cc73e
More recommendations
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
876.7
INR
Average target price
830.5
INR
Spread / Average Target
-5.27%
High Price Target
965
INR
Spread / Highest target
+10.07%
Low Price Target
710
INR
Spread / Lowest Target
-19.01%
Consensus detail
Consensus revision (last 18 months)
Trading Rating
Investor Rating
ESG Refinitiv
B
EPS Revisions
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- STAR Stock
- Consensus Strides Pharma Science Limited
